Genelux Corporation Common Stock (GNLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has a cash flow conversion efficiency ratio of -0.264x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.06 Million) by net assets ($22.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Genelux Corporation Common Stock to measure how many days the company can operate on defensive assets alone.
Genelux Corporation Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Genelux Corporation Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genelux Corporation Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genelux Corporation Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coraza Integrated Technology Bhd
KLSE:0240
|
0.243x |
|
Micro Systemation AB (publ)
ST:MSAB-B
|
0.606x |
|
Mercator Medical S.A.
WAR:MRC
|
0.052x |
|
Super Energy Corporation Public Company Limited
BK:SUPER-R
|
0.082x |
|
UBM Development AG
VI:UBS
|
0.009x |
|
DNF Co.Ltd
KQ:092070
|
0.041x |
|
Thac Mo Hydropower JSC
VN:TMP
|
0.122x |
|
ABL Group ASA
OL:ABL
|
0.040x |
Annual Cash Flow Conversion Efficiency for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Genelux Corporation Common Stock from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Genelux Corporation Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.54 Million | $-25.27 Million | -2.189x | -170.91% |
| 2024-12-31 | $26.27 Million | $-21.23 Million | -0.808x | +22.40% |
| 2023-12-31 | $19.47 Million | $-20.27 Million | -1.041x | -1143.31% |
| 2022-12-31 | $-35.78 Million | $-3.57 Million | 0.100x | -49.82% |
| 2021-12-31 | $-33.11 Million | $-6.58 Million | 0.199x | -37.47% |
| 2020-12-31 | $-22.66 Million | $-7.21 Million | 0.318x | +9.24% |
| 2019-12-31 | $-24.81 Million | $-7.22 Million | 0.291x | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more